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Abstract
Purpose—Superparamagnetic iron oxide nanoparticles (IONPs) are being investigated for brain
cancer therapy because alternating magnetic field (AMF) activates them to produce hyperthermia.
For central nervous system applications, brain entry of diagnostic and therapeutic agents is usually
essential. We hypothesized that AMF-induced hyperthermia significantly increases IONP blood–
brain barrier (BBB) association/uptake and flux.
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Methods—Cross-linked nanoassemblies loaded with IONPs (CNA-IONPs) and conventional
citrate-coated IONPs (citrate-IONPs) were synthesized and characterized in house. CNA-IONP
and citrate-IONP BBB cell association/uptake and flux were studied using two BBB Transwell®
models (bEnd.3 and MDCKII cells) after conventional and AMF-induced hyperthermia exposure.
Results—AMF-induced hyperthermia for 0.5 h did not alter CNA-IONP size but accelerated
citrate-IONP agglomeration. AMF-induced hyperthermia for 0.5 h enhanced CNA-IONP and
citrate-IONP BBB cell association/uptake. It also enhanced the flux of CNA-IONPs across the two
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in vitro BBB models compared to conventional hyperthermia and normothermia, in the absence of
cell death. Citrate-IONP flux was not observed under these conditions. AMF-induced
hyperthermia also significantly enhanced paracellular pathway flux. The mechanism appears to
involve more than the increased temperature surrounding the CNA-IONPs.
Conclusions—Hyperthermia induced by AMF activation of CNA-IONPs has potential to
increase the BBB permeability of therapeutics for the diagnosis and therapy of various brain
diseases.
Keywords
alternating magnetic field; blood-brain barrier permeability; cross-linked nanoassemblies; flux;
superparamagnetic iron oxide nanoparticles
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Introduction
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Brain capillary endothelial cells cooperate with pericytes, astrocytes, and neurons to
generate the unique barrier properties of the blood–brain barrier (BBB), which is part of the
neurovascular unit that plays a crucial role in safeguarding the brain from potentially
harmful endogenous and exogenous substances circulating in the blood. The BBB, with its
tight junctions and efflux transporters, restricts the entry of most therapeutic agents,
frequently resulting in unsuccessful treatment of brain diseases (1). Because of this
challenge, research efforts have focused for decades on the development of strategies to
more effectively deliver drugs to the central nervous system (CNS). A promising approach
to overcome limited drug flux into the CNS is the employment of multifunctional
nanoparticles (2). Numerous studies have shown that nanoparticle uptake into brain
parenchyma can occur through receptor-mediated endocytosis, absorptive transcytosis, and
tight junction opening (3,4). However, many in vivo reports of nanoparticle CNS
applications, particularly those of metal-based nanoparticles, showed only indirect evidence
of flux across the BBB into brain parenchyma. Given the distance between microvessels in
the brain is less than 20 μm (e.g. see (5)), to be able to definitively state that a nanomaterial
has crossed the in vivo BBB requires a high resolution imaging method, such as electron
microscopy or confocal laser scanning microscopy, or a separation method such as described
by Triguero et al. (6). Many reports concluded the nanomaterial entered the brain based on
elemental analysis, fluorescence, or radioactivity using detection methods that do not
differentiate substances in the vascular compartment of the brain or associated with the BBB
vs. brain parenchyma, such as elemental analysis, e.g. (7), radioactivity, e.g. (8), or based
their conclusions only on therapeutic efficacy in an animal model (9). The ability of
nanoparticles to distribute from the luminal to the basolateral sides of the BBB or bloodtumor barrier will determine whether they can deliver drugs to specific brain tissues, such as
brain tumors. A better understanding of nanoparticle association/uptake with, and flux
across, biological barriers including the highly regulated BBB, is urgently needed.
Superparamagnetic iron oxide nanoparticles (IONPs) are useful to provide insights into
these issues as well as having diagnostic and therapeutic applications. They can be activated
by an alternating magnetic field (AMF) to generate local hyperthermia (10). Iron oxide
nanoparticles are known to generate heat due to molecular vibration under AMF. The
Pharm Res. Author manuscript; available in PMC 2016 May 01.
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mechanisms underlying the production of heat for nanoparticles of the size utilized in this
study (<50 nm) include the Neel mode (rotation of the magnetic moment of the IONPs away
from its crystal lattice toward the alternating magnetic field to minimize its potential energy,
providing internal friction due to the movement of the magnetic moment) and rotational
friction provided by the viscous drag of the suspending medium as the IONPs align with the
magnetic field. Mild hyperthermia (40 to 44°C) is cytotoxic to tumor cells (11). AMF
activation of IONPs leads to a localized hyperthermia resulting in brain cancer cell death in
vitro and in vivo (12,13). Mild whole body hyperthermia can increase BBB permeability,
which has potential for brain therapeutic application (14). Whole body hyperthermia (42°C
for 0.5 h) significantly increased flux of doxorubicin delivered in a temperature-sensitive
liposome across the BBB in vitro and in vivo (15). However, whole body hyperthermia led
to heat stress and caused CNS toxicity, including edema (14,16). One possibility is to
develop an IONP nanocarrier system which can generate local hyperthermia to increase
BBB permeability and brain accumulation for potential CNS diagnostic and therapeutic
applications. Whether the BBB permeability of IONPs can be enhanced by taking advantage
of their unique superparamagnetic properties, such as AMF-induced hyperthermia, needs to
be investigated.
There are few reports of IONP association/uptake with, and flux across, the BBB. A recent
study evaluated the uptake transport of surface-modified IONPs by human-derived
endothelial cells; no IONP flux across the cells was observed (17). The lack of IONP flux
across the BBB limits their applications to target the brain for diagnostic and therapeutic
applications.
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In this study, conventional citrate-coated IONPs (citrate-IONPs) and cross-linked
nanoassemblies loaded with IONPs (CNA-IONPs) (10) were used as IONP nanocarrier
models to investigate the effect of AMF-induced hyperthermia on IONP permeability and
flux across the BBB.

Author Manuscript

Citrate-IONPs were prepared by co-precipitating ferric and ferrous ions in the presence of
ammonium hydroxide with citric acid as a stabilizer, while CNA-IONPs were prepared by
forming IONPs inside the core of poly(ethylene glycol)-poly(aspartate) block copolymer
cross-linked nanoassemblies. Our previous research showed that CNA-IONPs are stable for
30 h in cell culture medium in the absence and presence of AMF (10). No cytotoxicity was
seen in mouse brain endothelial-derived (bEnd.3) cells exposed to ≤10 mg/mL CNA-IONPs
for 30 h (10). Incorporating IONPs in CNAs significantly improved particle stability and
biocompatibility compared to citrate coating, providing a promising IONP formulation.
Citrate-IONPs, as one of the most common and commercially available IONPs, were used as
a control.
The objective of this study was to determine the potential effect and mechanism of AMFinduced hyperthermia on IONP association/uptake with, and flux across, BBB models. We
evaluated citrate-IONP and CNA-IONP association/uptake, flux across, and effects using
two in vitro BBB models (bEnd.3 and Madin-Darby canine kidney II (MDCKII) cells) in
Transwells®. Although bEnd.3 cells form tighter junctions than some other BBB-derived
cell lines, such as bEnd.5 cells and mouse brain endothelial cell 4 (18), the confluent bEnd.3
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cell monolayer does not recapitulate the degree of tightness of in vivo BBB junctions, which
is typical for BBB models composed of only BBB-derived endothelial cells (19). The bEnd.
3 cell layer model better represents the clinically relevant blood-tumor barrier than the BBB.
To study a better BBB model, we also used MDCKII cells, a non-cerebral-derived cell line,
because they express the components of the BBB tight junctions, are known to form tight
junctions very well (20,21), and have been used as a surrogate in vitro BBB model (22).
Results of this study provide a better understanding how AMF-induced hyperthermia
influences IONP cell association/uptake and flux across the BBB, which will be beneficial
for improving their CNS applications, such as brain tumor diagnosis and therapy.

Materials and Methods
Materials
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The chemicals used to prepare the citrate-coated IONPs (citrate-IONPs) and cross-linked
nanoassemblies loaded with superparamagnetic iron oxide nanoparticles (CNA-IONPs) have
been described (10). The immortalized mouse brain endothelial cell line bEnd.3 (American
Type Culture Collection, Manassas, VA) and MDCKII cells (European Collection of Cell
Cultures, Salisbury, UK) were used. Dulbecco's Modified Eagle Medium (DMEM) and
minimum essential medium with Earle's salts (MEM) were obtained from Mediatech,
Manassas, VA. Fetal bovine serum (FBS) was obtained from Atlanta Biologicals,
Lawrenceville, GA. Penicillin and streptomycin were obtained from Invitrogen, Grand
Island, NY. Transwell® filters were obtained from Corning Costar, Lowell, MA. Ferrozine
and neocuproine were obtained from the Hach Company, Loveland, CO. Lucifer yellow was
obtained from Sigma-Aldrich, St. Louis, MO. Bicinchoninic acid assay kits (BCA Protein
Assay Kits) were obtained from Thermo Fisher Scientific, Waltham, MA. Twelve well
plates were obtained from BD Falcon, San Jose, CA.
Preparation and Characterization of Citrate-IONPs and CNA-IONPs
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Citrate-IONPs and CNA-IONPs were synthesized and characterized as described (10,23).
Briefly, citrate-IONPs were prepared by adding ammonium hydroxide dropwise to a mixture
of ferric chloride hexahydrate (Fe3+) and ferrous chloride tetrahydrate (Fe2+) dissolved in
deionized water (Fe3+:Fe2+ = 2:1) under a nitrogen atmosphere at 85°C and then stabilizing
the IONPs with citric acid (2 equivalents). The citrate-IONPs were collected by a magnet
and washed repeatedly using ethanol prior to overnight vacuum drying. CNA-IONPs were
prepared by a similar method, replacing citric acid with cross-linked poly(ethylene glycol)poly(aspartate) block copolymer nanoassemblies comprising 5 kDa PEG and 40 repeating
units of aspartate that were chemically conjugated with 1,8-diaminooctane. In contrast to
citrate-IONPs, CNA-IONPs dispersed in water stably, and were thus purified by filtration
and dialysis prior to freeze drying. Both citrate-IONPs and CNA-IONPs were prepared in
bulk, stored in powder forms at −20°C, and reconstituted in aqueous solutions (PBS or cell
culture medium) immediately before use. Their particle size was measured each time by
DLS. The stability of citrate-IONPs (0.05 mg/mL) and CNA-IONPs (2.5 mg/mL) in the cell
culture media described below was monitored for 6 h after 0.5 h exposure to 37°C, 43°C, or
AMF using dynamic light scattering (DLS) analysis (90Plus NanoParticle size distribution
analyzer, Brookhaven Instruments, Holtsville, NY).
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bEnd.3 and MDCKII cells were cultured in DMEM and MEM with 10 and 5% FBS,
respectively, and 100 U/ml penicillin and 100 mg/ml streptomycin at 37°C in a humidified
incubator with 5% CO2. They were used from passages 5 through 10 and 45 through 60,
respectively.
Transwell® Cultures
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bEnd.3 and MDCKII cells were seeded on Transwell® filters (4.67 cm2 for the 6-well
polycarbonate plate, pore size 3.0 μm) at a density of 200,000 cells/cm2, and grown to a
monolayer (Fig. 1). bEnd.3 assays were performed 7 to 10 days after seeding (24), when
transendothelial electrical resistance was >120 Ω·cm2, measured using a RMA321-MillicellERS voltohmmeter (Millipore Corp, Billerica, MA). The apparent permeability coefficient
(Papp) of LY at 37°C was 3.81±0.17× 10−6 cm/s (Table I), similar to a previous report (24).
MDCKII assays were performed 4 days after seeding (25), when resistance was >170
Ω·cm2.
Ferrozine Iron Assay
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The iron content of the nanoparticle dispersions, cell culture media, nanoparticle-loaded
cells, and control cells was determined using a ferrozine assay (26,27). Fifty μL of
appropriately diluted sample was mixed with 50 μL of 1.4 mM HCl and 20 μL 2 M ascorbic
acid and incubated at 70°C for 1 h. After cooling to room temperature, 30 μL of iron
detection reagent (6.5 mM ferrozine, 6.5 mM neocuproine, 2.5 M ammonium acetate, and 1
M ascorbic acid in water) was added. After 30 min, the solution in each tube was transferred
into a well of a 96 well plate and absorbance measured at 550 nm on a microplate reader. A
standard curve was prepared with 0, 0.1, 0.2, 0.5, 1, 2, 5, and 10 μg/mL iron, and similarly
treated.
AMF-Induced Heating Profiles
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The heating profiles of AMF-activated CNA-IONPs (2.5 mg/mL) were evaluated in the
Transwell® cell model. The heating profile for citrate-IONPs was not studied because our
previous study showed that 0.05 mg/mL IONPs provide insufficient iron to increase the cell
culture medium temperature and higher concentrations kill the cells (10). AMF was induced
by a Taylor Winfield induction power supply (Taylor-Winfield Technologies
MMF-3-135/400-2, Columbus, OH) equipped with a 15 mm diameter, 5 turn solenoid. The
AMF field parameters were 33.4 kA/m at 300 kHz. The temperature of the medium in the
Transwell® donor chamber was measured every 0.25 s using a Fluoroptic® thermometer
(LumaSense Technologies, Santa Clara, CA). The initial medium temperature was 37°C.
Paracellular Flux
To measure paracellular pathway permeability, 100 μM LY was added to the Transwell®
donor side medium in every flux study. Media samples (100 μL) from the donor chamber
were collected at time zero and from the receiving chamber at different times for LY
quantification. LY concentration was measured in the donor and receiving chamber at the
end of each experiment. Fluorescence was determined in a SpectraMax M5 Multi-Mode
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Microplate Reader (Molecular Devices, Sunnyvale, CA) at λex/λem = 450/530 nm and
compared with a standard curve with a linear range from 0.5 to 30 μM in DMEM (bEnd.3
cells) or MEM (MDCKII cells) (28).
Citrate-IONP and CNA-IONP Cell Association/Uptake and Flux Using bEnd.3 and MDCKII In
Vitro BBB Models

Author Manuscript

Citrate-IONPs (0.05 mg/mL) or CNA-IONPs (2.5 mg/mL) and 100 μM LY were introduced
into the Transwell® donor chamber. The concentrations were based on results of our
previous cytotoxicity study (10). To determine cell association/uptake the cells were
exposed to 37 or 43°C (the latter to compare to AMF-induced hyperthermia) or AMF for 0.5
h. All were then maintained at 37°C for 6 h. IONP cell association/uptake was terminated by
medium removal and addition of ice cold solution containing 137 mM NaCl and 10 mM
HEPES at pH 7.4 (29). Cells were trypsinized using 0.25% trypsin-EDTA for 5 min at 37°C
and the suspension centrifuged. The cell pellet was re-suspended with medium. A trypan
blue exclusion test was performed to assess cell viability (30). Protein concentrations were
measured using the BCA Protein Assay Kit. At least three replications of the cell
association/uptake experiments were conducted. To determine CNA-IONP flux across the
MDCKII in vitro BBB model, CNA-IONPs (2.5 mg/mL) and LY were added to the donor
chamber medium. The cells were incubated for 0.5, 1, 2, or 4 h at 43°C or exposed to 0.5 h
AMF-induced hyperthermia followed by incubation at 37°C for 6 h. These experiments were
performed in triplicate wells and repeated once in triplicate wells.
Citrate-IONP and CNA-IONP Cell Localization Using Transmission Electron Microscopy
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bEnd.3 and MDCKII cells were seeded on 12 well plates at a density of 200,000 cells/cm2.
A cell association/uptake experiment was performed 3 days after seeding. The cells were
exposed to cell culture medium containing 0.05 mg/mL citrate-IONPs or CNA-IONPs for 2
h, and then quickly washed with ice cold saline 3 times. The cells were fixed in 3.5%
glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4 for 1 h at 4°C. Samples were dehydrated
in ascending concentrations of ethanol and embedded in Eponate 12. After polymerization,
blocks were sectioned at 80 nm and viewed with a Philips Tecnai 12 Biotwin electron
microscope (FEI, Hillsboro, OR).
Data and Statistical Analysis
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The apparent permeability coefficient (Papp) of LY and CNA-IONPs and their influx rates
were calculated by linear regression. The Papp (in cm/s) was calculated using the equation:
Papp=(ΔQ/Δt)/(area*CD) (25). ΔQ/Δt is the linear appearance rate obtained from the profile
of the transported amount of the substrate against time (mg/s). Area is the surface area of the
cell monolayer (4.67 cm2 for a 6-well plate). CD is the initial donor concentration of LY or
nanoparticle (mg/mL). Results from the first 6 h of flux data were used when the linear
regression R2 was >0.8. The % of IONPs /LY in receiving chamber = mass amount of
IONPs/LY in the receiving chamber at certain time point × 100%/initial donor dose. Mass
balance of LY = (LY in the receiving and donor chambers) × 100%/initial donor dose.
Bartlett's test was used to determine if samples had equal variances. One-way ANOVA
followed by Tukey's test was used to test for significant differences between citrate-IONP
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and CNA-IONP cell association/uptake and apparent permeability coefficients among the
treatment groups. Two-way ANOVA followed by the Bonferroni multiple comparisons
procedure was used to identify significant flux differences among the treatment groups and
times using GraphPad Prism. The results of the statistical analysis for one-way and two-way
ANOVAs are reported as F(df effect, df error) = F-value and P-value. All statistical tests
were conducted using GraphPad Prism (GraphPad Software, San Diego, CA). All results are
reported as mean±standard deviation (SD). Statistical significance was accepted at p<0.05.

Results
Characterization of Citrate-IONP and CNA-IONP Size, Stability, and AMF Response
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Citrate-IONPs had a primary particle size of ∼10 nm, were 90±10 nm in water at 0.2
mg/mL, but agglomerated to >400 nm and precipitated in PBS and cell culture medium (10).
This agglomeration was accelerated by conventional (43°C) and AMF-induced
hyperthermia, resulting in >800 nm agglomerates (results not shown).
The CNA-IONPs were 25±3 nm measured by DLS. IONP loading of CNAs was 25±3 and
25±1 wt % determined by thermogravimetric analysis and inductively coupled plasma mass
spectrometry analysis, respectively. AMF-induced hyperthermia had no effect on CNAIONP size in cell culture medium at 30 h (Fig. 2a). AMF activation of CNA-IONPs (2.5
mg/mL) in cell culture medium increased the medium temperature to 41°C in 10 min (Fig.
2b).
Citrate-IONP and CNA-IONP Association/Uptake and Flux Using a bEnd.3 In Vitro BBB
Model
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Citrate-IONP cell association/uptake significantly increased in the conventional
hyperthermia and AMF-induced hyperthermia groups compared to control (F(2,6) = 24,
P<0.0014) (Fig. 3a). In contrast, analysis of iron concentration showed CNA-IONP cell
association/uptake did not change significantly in the conventional hyperthermia or the
AMF-induced hyperthermia groups compared to the 37°C controls (Fig. 3b). TEM
observations provided insight into the different cell association/uptake iron levels.
Agglomerated citrate-IONPs (close to micrometer size) (Fig. 4a) with their primary size
around 10 nm (Fig. 4b) were observed inside bEnd.3 cells. After analysis of three separately
prepared TEM samples and two sections from each sample, CNA-IONPs were occasionally
found in three samples (Fig. 4c). CNA-IONP cell association was at least 10 times lower
compared with citrate-IONPs (Fig. 3b vs. a; Fig. 4c vs. b).

Author Manuscript

Flux of citrate-IONPs through the bEnd.3 monolayer did not increase over 6 h and was
similar among the three treatment groups (Fig. 3c). The flux of CNA-IONPs significantly
increased from 1 to 6 h in the AMF-induced hyperthermia group compared with the control
and conventional hyperthermia groups (Fig. 3d). The paracellular flux rates measured by LY
were linear for the first 6 h in the presence of citrate-IONP- (Fig. 3e) and CNA-IONP- (Fig.
3f) treated groups. Mass balance of LY for the bEnd.3 model was between 89 and 112%.
Paracellular flux of LY in the CNA-IONP treated group, but not the citrate-IONP-treated
group, was significantly increased in the AMF-induced hyperthermia group from 2 to 6 h
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(Fig. 3e and f). The Papp of LY was similar in the control and conventional hyperthermia
groups in the presence of citrate-IONPs and CNA-IONPs (Fig. 3e and f; Table I). However,
the Papp of CNA-IONPs in the AMF-induced hyperthermia group significantly increased
(148%; F(2,7) = 19, P<0.0016), and LY to a lesser extent (90%; F(2,7) = 280, P<0.0001),
compared with the normothermic control group (Table I). The trypan blue exclusion test
showed no cell death in any experiments (results not shown). Since the flux was linear only
for the first 6 h, the rest of this study only observed the flux rate for 6 h.
Effect of AMF-Induced vs. Conventional Hyperthermia on CNA-IONP Cell Association/
Uptake and Paracellular Flux Using a MDCKII In Vitro BBB Model

Author Manuscript
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In the absence of AMF-induced hyperthermia, CNA-IONP and LY flux were temperatureand concentration-independent in the MDCKII in vitro BBB model (Fig. 5). Total flux was
<0.2% over 6 h. MDCKII cell association/uptake of CNA-IONPs was significantly
increased in the AMF-induced hyperthermia group compared to the control and
conventional hyperthermia groups (F(2,7) = 10, P<0.0081) (Fig. 6a). AMF-induced
hyperthermia significantly increased CNA-IONP flux (Fig. 6b). The Papp of CNA-IONPs
(F(2,7) = 27, P<0.0005) increased much more than LY (F(2,7) = 7, P<0.019) in the AMF
group, 128% and 20%, respectively, compared with controls (Table I). The trypan blue
exclusion test showed no cell death in any experiments (results not shown). Lucifer yellow
Papp was 0.49±0.03×10−6 cm/s at 37°C (Table I). The LY Papp was 0.46 to 0.50×10−6 cm/s
for the first 6 h after 0.5, 1, and 2 h exposure at 43°C followed by 37°C for 6 h. However,
after incubation at 43°C for 4 h, the Papp of LY significantly increased 22% (Papp,
0.61±0.05× 10−6 cm/s) compared with the normothermic control and similar to the LY Papp
across MDCKII cells 6 h after exposure to AMF-induced hyperthermia for 0.5 h (Table I).
Paracellular flux (LY) was significantly greater across the MDCKII cells starting 2 h after
exposure to AMF-induced hyperthermia (0.5 h) compared with the control and conventional
hyperthermia (Fig. 6c). Mass balance of LY for the MDCKII model was between 92 and
108%. The trypan blue exclusion test did not reveal cell death in any experiments after cell
exposure to 43°C for 4 h, or AMF-induced hyperthermia for 0.5 h, followed by 6 h at 37°C
(results not shown).

Discussion
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Biocompatibility and stability in biological environments, such as cell culture medium or
blood, are crucial for nanoparticles to serve as good candidate carriers across the BBB
(31,32). In this study, we investigated citrate-IONP and CNA-IONP association/uptake, flux
across, and effects on two in vitro models of the BBB under normothermic, conventional
hyperthermic, and AMF-induced hyperthermic conditions. Citrate-IONPs agglomerated very
rapidly in cell culture medium to >400 nm (10). Increased temperature enhanced their
agglomeration. Even though citrate-IONPs agglomerated close to micrometer size in vitro,
they were still able to be taken up by BBB cells. The TEM results suggested that citrateIONPs were taken up by endocytosis. Citrate-IONPs did not show increased flux across
bEnd.3 cells over 6 h, nor did increased temperature induced by conventional hyperthermia
or AMF increase citrate IONP flux across bEnd.3 cells. Our results demonstrated that
citrate-IONPs can enter BBB cells through an endocytosis pathway, however, they did not
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cross the in vitro BBB model. No transcytosis of citrate-IONPs across the BBB suggests
they lack potential therapeutic CNS applications.
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CNA incorporation of IONPs improved its stability (size ∼25 nm, Fig. 2a) and
biocompatibility compared to citrate IONPs, without loss of AMF-induced hyperthermia
properties (10). Our previous research demonstrated that CNAs prepared from
biocompatible poly(ethylene glycol)-poly(aspartate) [PEG-p(Asp)] block copolymers
provided stability for nanoparticles, by entrapping them in the core of a charged cage
produced by locally highly concentrated carboxylate groups that isolate the CNAs and
stabilize them from interaction among themselves and environmental cations. CNAs provide
the ability to incorporate hydrophobic and amphiphilic payloads without changing particle
size (23,33). CNA-IONP flux increased with time across bEnd.3 cells at 37°C, resulting in
flux of less than 5% in 6 h. Flux across MDCKII cells was less than 0.2%. We also
demonstrated that CNA-IONP flux was concentration independent, providing evidence that
it was through a non-diffusion mechanism (Fick's law). More studies are needed to
investigate the mechanisms of IONP flux across the BBB. This very limited IONP flux is
consistent with a report of charged IONP flux using a human brain derived BBB model, in
which they did not observe any IONP flux over 24 h (17). The Papp (0.05 to 1× 10−8 cm/s)
of eleven iron oxide 200 to 1100 nm particles investigated using a bEnd.3 BBB model
marginally supported the conclusion that larger particles have increased difficulty crossing
the BBB (34). The Papp of CNA-IONPs is at least 10 times higher than these results. CNAIONPs, with a relatively stable size <40 nm in cell culture medium, showed their greater
ability to cross the BBB than other IONP carriers.
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AMF-induced hyperthermia doubled the Papp of CNA-IONPs in the bEnd.3 model during
the first 6 h. Ten percent of CNA-IONPs crossed the bEnd.3 monolayer within 6 h. The LY
flux was also significantly increased, providing evidence that AMF-induced hyperthermia in
the presence of CNA-IONPs opened the paracellular pathway to increase CNA-IONP flux.
The lack of observed cell death ruled that out as the cause of increased flux. The cell uptake/
association of CNA-IONPs was ∼10 times lower than citrate-IONPs. The low cell uptake of
CNA-IONP was consistent with CNA-IONPs crossing the BBB mainly through the
paracellular pathway after AMF-induced hyperthermia in the bEnd.3 in vitro BBB model. A
recently published study also demonstrated that a static externally-applied magnetic field
can increase IONP permeability through the paracellular pathway of bEnd.3 cells in vitro
(35). The present report is the first to show that AMF-induced hyperthermia significantly
increases CNA-IONP flux across in an in vitro BBB model with low toxicity. AMF-induced
hyperthermia mediated by IONPs is one approach to potentially increase IONP BBB
permeability and flux for CNS diagnosis and therapy.
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The Papp of LY across MDCKII cells exposed to AMF increased only 20% compared to
controls, whereas flux increased 90% in the bEnd.3 model. AMF-induced hyperthermia
increased the Papp of CNA-IONPs 148% in the bEnd.3 model and 128% in the MDCKII
model. In general, a similar trend was observed in BBB permeability changes (LY flux)
induced by AMF-induced hyperthermia using the two in vitro BBB models. However, the
‘leaky’ bEnd.3 Transwell® model's paracellular pathway flux was more sensitive to
conventional and AMF-induced hyperthermia than MDCKII cells. Previous studies also

Pharm Res. Author manuscript; available in PMC 2016 May 01.

Dan et al.

Page 10

Author Manuscript
Author Manuscript

showed a threshold at 43°C for BBB disruption induced by conventional hyperthermia in
normal brain tissue (36,37). However, in a leaky BBB, such as the blood-tumor barrier
which was more sensitive to conventional hyperthermia, permeability increased at a lower
temperature (38). The bEnd.3 Transwell® model can provide insight into the effect of AMFinduced hyperthermia on leaky BBB conditions such as the blood-tumor barrier. Even
though MDCKII cells are not a BBB-derived cell line, they were shown to be a good in vitro
model to predict the extent of brain exposure and the rate of brain association/uptake in vivo
for several CNS drug candidates (39). However, there are major differences between
MDCKII epithelial and brain endothelial cells, such as expression of different transporters
(40). Comparing these two in vitro BBB models, the MDCKII cell model better predicts
whether AMF-induced hyperthermia changes paracellular flux in normal brain tissue
because they form tighter junctions than the bEnd.3 cells. Because of the unique
physicochemical properties and different cell association/uptake mechanisms of
nanoparticles compared with small drug candidates, further studies were needed to
investigate the correlation between nanoparticle flux across the bEnd.3 and MDCKII
Transwell® models and the BBB in vivo.

Author Manuscript

The potential application of conventional hyperthermia to increase BBB permeability has
been investigated for decades. Numerous studies showed that conventional hyperthermia can
increase BBB permeability depending on heat magnitude and duration (14,16). However,
the difference between conventional hyperthermia and AMF-induced hyperthermia on BBB
permeability has not been well studied. The Papp of LY and CNA-IONPs significantly
increased (90 and 148% respectively) in the AMF-induced hyperthermia group compared
with the conventional hyperthermia group bEnd.3 cells. There was no significant difference
between the 37 and 43°C groups, suggesting AMF-activation of CNA-IONPs increased
BBB permeability not only by simple heating but also other factors such as IONP vibration
or difference in IONP surface temperature vs. the surrounding temperature. CNA-IONPs can
bind to the cell surface and vibrate under AMF, mechanically increasing BBB permeability.
Other research demonstrated that cell surface bound IONPs can mechanically activate
certain cell surface receptors (41). The temperature we measured was the environmental
temperature in the Transwell® medium rather than the IONP surface temperature. Previous
research showed that IONP surface temperature can be up to 20°C higher relative to the
surrounding regions (42). Further research needs to be conducted to investigate how CNAIONPs associate with BBB cells and the role of temperature and mechanical effects on BBB
permeability.

Author Manuscript

AMF-induced hyperthermia can increase paracellular permeability more effectively than
conventional hyperthermia. Our results showed that conventional hyperthermia (43°C) did
not influence paracellular flux up to 2 h and that flux significantly increased at 43°C after 4
h. A previous whole body hyperthermia study with rats also showed BBB permeability
changes were highly dependent on heat magnitude and duration. No BBB permeability
change was observed (within 2 h) under whole body hyperthermia, but BBB permeability
increased after 4 h whole body hyperthermia (16). We did not observe any cell death even
after 4 h conventional hyperthermia at 43°C. However, whole body hyperthermia leads to
heat stress causing numerous CNS toxicities such as edema and neuropil damage (43). Our
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results also showed that the Papp of LY after conventional hyperthermia at 43°C for 4 h was
similar to the Papp of LY at AMF-induced hyperthermia for 0.5 h. AMF-induced
hyperthermia can increase BBB permeability similar to conventional hyperthermia at a
lower cell medium temperature and shorter time without cell death in vitro. Previous
research showed that 0.5 h AMF-induced hyperthermia killed head and neck cancer cells in
mice without harming normal cells (44). Furthermore, previous research also demonstrated
that AMF-induced hyperthermia only led to a transient BBB permeability increase in vivo.
Their results showed that 0.5 h AMF-induced hyperthermia can increase the BBB
permeability transiently and the BBB permeability recovered 2 h after hyperthermia
treatment in mice (45). In the present stu dy AMF-induced hyperthermia showed the
potential advantages of transiently increased BBB permeability and reduced toxicity
compared with conventional hyperthermia, potentially increasing the brain targeting of
IONPs and their pharmacotherapeutic efficacy.
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Conclusions

Author Manuscript

CNA-IONPs showed stability in a mammalian tissue (cell culture) relevant medium. Flux
across bEnd.3 and MDCKII in vitro BBB models was low under normothermic conditions.
AMF-induced hyperthermia for 0.5 h enhanced CNA-IONP cell association/uptake and flux
in the absence of cell death. In contrast, citrate IONPs agglomerated in cell culture medium
and were taken up by, but did not flux through, the bEnd.3 BBB model. AMF-induced
hyperthermia enhanced the BBB association/uptake and permeability of CNA-IONPs more
effectively than conventional hyperthermia, by mechanisms in addition to elevated
temperature around the IONPs. CNA-IONPs activated by AMF can produce a quantifiable,
controllable hyperthermia in a defined area which is required for clinical applications. AMFinduced hyperthermia provides an approach to deliver IONPs across the BBB with low
toxicity for potential therapeutic and diagnostic CNS applications.
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AMF

Alternating magnetic field

BBB

Blood–brain barrier

bEnd.3

A transformed murine brain/cerebral cortex endothelial cell line

Citrate IONPs

Citrate iron oxide nanoparticles

CNA-IONPs

Cross-linked nanoassembly iron oxide nanoparticles

CNS

Central nervous system

DLS

Dynamic light scattering

IONPs

Iron oxide nanoparticles

LY

Lucifer yellow

MDCKII

Madin-Darby canine kidney II cells

Papp

Apparent permeability coefficient

Author Manuscript
Pharm Res. Author manuscript; available in PMC 2016 May 01.

Dan et al.

Page 15

Author Manuscript
Author Manuscript

Fig. 1.

Schema of the Transwell® system and AMF used for cell association/uptake and flux
studies.
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AMF did not change CNA-IONP nanoparticle size but produced hyperthermia. Particle
stability characterization results determined by DLS after exposure to 37°C for 30 h (n=6),
43°C (0.5 h) followed by 37°C for 30 h (n=6), or AMF (0.5 h), followed by 37°C for 30 h
(n=4) (a). Representative heating profile of CNA-IONPs in cell culture medium for finetuned remote heating with 0.5 h application of AMF (b). Cell culture medium exposed to
AMF that contained no CNA-IONPs (37°C) served as the control.
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Fig. 3.
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Citrate-IONP and CNA-IONP cell association/uptake and flux across bEnd.3 cells. CitrateIONP bEnd.3 cell association/uptake after 37°C for 6 h (n=3), conventional hyperthermia at
43°C (0.5 h) followed by 37°C for 6 h (n=3), or AMF-induced hyperthermia (0.5 h)
followed by 37°C for 6 h (n=3) (a). CNA-IONP bEnd.3 cell association/uptake after 37°C
for 6 h (n=3), conventional hyperthermia at 43°C (0.5 h) followed by 37°C for 6 h (n=3), or
AMF-induced hyperthermia (0.5 h) followed by 37°C for 6 h (n=4) (b). Citrate-IONP flux
across bEnd.3 cells (c). CNA-IONP flux across bEnd.3 cells (d). The paracellular flux
across bEnd.3 cells measured by LY for the first 6 h in the Citrate-IONP treated group (e)
and CNA-IONP treated group (f). Error bars not seen in panels C, D, E, and F are less than
the symbol height. * Significantly different compared to 37°C in panel A or compared to
37°C and conventional hyperthermia in panel D and panel F.
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Fig. 4.

Citrate IONP and CNA-IONP cell localization. Transmission electron microscopy results of
the cellular localization of the Citrate-IONPs (a and b) and CNA-IONPs (c) in bEnd.3 cells
at 2 h. The arrows indicate the location of IONPs inside the cells.
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Fig. 5.
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Paracellular permeability and CNA-IONP flux across the MDCKII in vitro BBB model. LY
(a) and CNA-IONP (b) flux at 2 concentrations and 2 temperatures (n=3).
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Fig. 6.

CNA-IONP cell association/uptake and CNA-IONP and Lucifer yellow flux across
MDCKII cells. CNA-IONP MDCKII cell association/uptake after 37°C for 6 h (n=3),
conventional hyperthermia at 43°C (0.5 h) followed by 37°C for 6 h (n=3), or AMF-induced
hyperthermia (0.5 h) followed by 37°C for 6 h (n=4) (a). CNA-IONP flux across a MDCKII
in vitro BBB model (b). The effect of conventional and AMF-induced hyperthermia on LY
flux across MDCKII cells after 43°C incubation (n=3) or AMF for 0.5 h followed by 37°C
for 6 h (n=4), compared to 37°C control (n=3) (c). * Significantly different compared to
AMF (0.5 h) in panel A or compared to 37°C and conventional hyperthermia in panels B
and C.
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Table I

Lucifer Yellow and CNA-IONP Apparent Permeability Coefficients
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Cell Type

Sample

bEnd.3

MDCKII

37°C

43°C (0.5 h)

AMF (0.5 h)

Lucifer yellow

3.81 ±0.17

4.04 ±0.14

7.25 ±0.28 *

CNA-IONPs

0.67 ±0.09

0.67 ±0.09

.66 ±0.37 *

Lucifer yellow

0.49 ±0.03

0.49 ±0.049

0.59 ±0.04 *

0.057 ±0.008

0.056 ±0.01

0.13 ±0.02 *

CNA-IONPs

The table shows apical-to-basolateral Papp coefficients of LYand CNA-IONPs using bEnd.3 and MDCKII in vitro BBB models at 37°C for 6 h
(n=3), 43°C (0.5 h) followed by 37°C for 6 h (n=3), or AMF (0.5 h) followed by 37°C for 6 h (n=4). Papp values are shown as 10−6 cm/s
*

Significantly different compared to 37 and 43°C (P<0.05)
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